Skip to main content
Vistin Pharma logo

Vistin Pharma — Investor Relations & Filings

Ticker · VISTN ISIN · NO0010734122 LEI · 5967007LIEEXZXFQY092 OL Manufacturing
Open in API
Filings indexed 519 across all filing types
Latest filing 2022-02-17 Earnings Release
Country NO Norway
Listing OL VISTN

About Vistin Pharma

https://www.vistin.com/

Vistin Pharma is a pharmaceutical company specializing in the production of Metformin Hydrochloride, an Active Pharmaceutical Ingredient (API). The company operates as a pure-play, global supplier, providing high-quality Metformin to pharmaceutical companies worldwide. In addition to the standard API, Vistin Pharma offers specialized grades such as Direct Compressible (DC) Metformin. With over 50 years of experience, the company emphasizes sustainable manufacturing from its dedicated European production facility.

Recent filings

Filing Released Lang Actions
Vistin Pharma ASA: Fourth quarter 2021 financial results
Earnings Release Classification · 99% confidence The document is titled "FOURTH QUARTER AND PRELIMINARY 2021 RESULTS" and contains detailed financial figures for Q4 2021 and the full year 2021, including Revenue, EBITDA, Balance Sheet items, and Cash Flow statements. It explicitly mentions that the financial report follows IAS 34 for interim financial reporting and presents comparative numbers for the previous year. This structure and content strongly indicate a comprehensive financial report covering a period shorter than a full year (quarterly/half-yearly). Therefore, it fits the definition of an Interim / Quarterly Report (IR). It is not an Earnings Release (ER) because it is a comprehensive report, not just highlights, and it is not a 10-K as it covers only Q4/FY2021, not the full fiscal year audited report. Q4 2021
2022-02-17 English
Vistin Pharma ASA: Fourth quarter 2021 financial results
Earnings Release Classification · 98% confidence The document explicitly announces the 'Fourth quarter 2021 financial results' for Vistin Pharma ASA, providing key figures like Revenue (MNOK 78), EBITDA (MNOK 12.2), and Net Profit (MNOK 7.2). This content structure—a summary of key financial metrics for a specific period (Q4 2021)—is characteristic of an Earnings Release (ER). Although it mentions that the Q4 report and presentation are enclosed and that a conference call will be held, the primary function of this text is the initial announcement of the results, making 'ER' the most appropriate classification over 'RPA' or 'CT'. The document length (2435 chars) is short, but it contains the core financial highlights, not just a notice to download them. Q4 2021
2022-02-17 English
New interim CEO
Board/Management Information Classification · 100% confidence The document text is very short (556 characters) and announces a change in senior management: Kjell-Erik Nordby is on sick leave, and Magnus Tolleshaug has been appointed as interim CEO. This directly corresponds to the definition of Board/Management Information.
2022-02-16 English
Vistin Pharma ASA: Invitation to Q4 2021 conference call
Call Transcript Classification · 95% confidence The document is an invitation announcing the date and time for a conference call related to the release of the Fourth Quarter 2021 results. It provides dial-in numbers and a webcast link for the event, which includes a Q&A session following the management discussion. This structure—announcing a call to discuss results—is characteristic of an Earnings Release (ER) or a Call Transcript (CT). Since this document is the *invitation* to the call, not the transcript itself, and it precedes the actual results discussion, it is most closely related to the event where results are discussed. However, the primary function here is to announce the event where the results will be discussed, which often accompanies or immediately follows an Earnings Release (ER). Given the options, a conference call transcript (CT) is for the recording of the call itself. This document is the announcement/invitation for that call. In many databases, the announcement of an earnings call, especially one tied directly to quarterly results, is often grouped with the Earnings Release (ER) or sometimes classified as a Call Transcript (CT) if the focus is on the call event. Since the text explicitly mentions the Q4 results release date and then immediately invites participants to the conference call about those results, it functions as a precursor to the detailed discussion. If the document were the transcript, it would contain the Q&A. If it were the ER, it would contain the key financial figures. As it is purely an invitation to the call, it fits best under Call Transcript (CT) as it pertains directly to the scheduled call event, or potentially RNS if it were too generic. Given the specific nature of announcing the Q&A session, CT is the most appropriate fit among the specific options, as it relates directly to the call event itself.
2022-02-08 English
Financial calendar
Report Publication Announcement Classification · 100% confidence The document is titled 'Financial calendar' and lists scheduled dates for various corporate events throughout 2021 and 2022, including 'Quarterly Report', 'Half-yearly Report', 'Annual Report', and 'Annual General Meeting'. It does not contain the content of any of these reports, but rather announces *when* they are scheduled to be released or occur. Since it is an announcement about the timing of future reports and meetings, it fits best as a general regulatory announcement or a schedule update. Given the options, it is a general announcement regarding corporate events and reporting schedules, which aligns most closely with the broad 'Regulatory Filings' (RNS) category, as there is no specific 'Financial Calendar' code, and it is not the report itself (like 10-K or IR). The document length is very short (489 chars), supporting the idea that it is an announcement rather than a full report.
2021-12-14 English
Vistin Pharma ASA: Mandatory notification of trade
Director's Dealing Classification · 99% confidence The document text is titled "KRT-1500 Skjema for melding om transaksjoner utført av personer med ledelsesansvar ('primærinnsidere') og deres nærstående" (KRT-1500 Form for reporting transactions carried out by persons discharging managerial responsibilities ('insiders') and their connected persons). It details a transaction (a 'Salg' or Sale) involving an insider ('Styremedlem' - Board Member) of Vistin Pharma ASA, including ISIN, price, volume, and date (29.10.2021). This structure precisely matches the definition of reporting personal share transactions by company directors and executives, which corresponds to the Director's Dealing category.
2021-10-29 Norwegian

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.